Phase III results on Diurnal's Chronocort published in endocrinology journal
UK-based Diurnal Group (AIM: DNL) has announced that the Journal of Clinical Endocrinology and Metabolism (JCEM) has published the Phase III trial and extension study for Chronocort (hydrocortisone modified-release hard capsules) in congenital adrenal hyperplasia (CAH).
Diurnal’s Phase III study was conducted in a total of 122 patients enrolled across 11 clinical sites, the largest ever interventional trial completed in CAH patients. Data are also presented from an open-label safety extension study for patients completing treatment in the Phase III trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze